Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 260fludarabine phosphate 163Methotrexate 124Rituximab 112Cytarabine 109Filgrastim 106fludarabine 92Busulfan 86Peripheral Blood Stem Cell Transplantation 83Etoposide 82Vincristine 80Radiotherapy 79Tacrolimus 73Mycophenolic Acid 72Antilymphocyte Serum 68Whole-Body Irradiation 66Melphalan 63Dexamethasone 63Cyclosporine 58Doxorubicin 51Methylprednisolone 44Alemtuzumab 44Prednisone 43Mercaptopurine 40Granulocyte Colony-Stimulating Factor 40pegaspargase 35Daunorubicin 34Clofarabine 33Thiotepa 31Asparaginase 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × NVP-BKM120 × Lymphoid × Clear all
NCT01396499 2016-11-01

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡